---
title: "SYRS.US (SYRS.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/SYRS.US/news.md"
symbol: "SYRS.US"
name: "SYRS.US"
parent: "https://longbridge.com/zh-CN/quote/SYRS.US.md"
datetime: "2026-03-14T05:18:39.920Z"
locales:
  - [en](https://longbridge.com/en/quote/SYRS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SYRS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SYRS.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/SYRS.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SYRS.US/news.md)


# SYRS.US (SYRS.US) — 相关新闻

### [Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials | SYRS Stock News](https://longbridge.com/zh-CN/news/235975819.md)
*2025-04-15T05:20:00.000Z*
> Rege Nephro Co., Ltd. has acquired Tamibarotene-related assets from Syros Pharmaceuticals to enhance its clinical trial 

### [Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares](https://longbridge.com/zh-CN/news/230147143.md)
*2025-02-28T21:40:05.000Z*
> Syros Pharmaceuticals said Friday its board approved the voluntary delisting of shares from the Nasdaq Stock Market and 

### [Nancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock](https://longbridge.com/zh-CN/news/221528394.md)
*2024-12-05T12:45:27.000Z*
> Nancy A. Simonian, Director of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), sold 37,070 shares of the company's stock on D

### [Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default](https://longbridge.com/zh-CN/news/219593798.md)
*2024-11-13T17:11:52.000Z*
> Syros Pharmaceuticals' stock plummeted 86.43% to 37 cents after its SELECT-MDS-1 Phase 3 trial of tamibarotene failed to

### [Syros Pharmaceuticals, Inc.  ( SYRS )  Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings](https://longbridge.com/zh-CN/news/213080487.md)
*2024-08-30T20:42:15.000Z*
> NEW YORK, Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating 

### [Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation | SYRS Stock News](https://longbridge.com/zh-CN/news/212926413.md)
*2024-08-29T14:00:00.000Z*
> Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) fo

### [Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | SYRS Stock News](https://longbridge.com/zh-CN/news/212679094.md)
*2024-08-27T14:00:00.000Z*
> Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Syros Pharmaceuticals, Inc. (SYRS) regardin

### [Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Investors to Seek Compensation for Alleged Wrongdoings | SYRS Stock News](https://longbridge.com/zh-CN/news/212558399.md)
*2024-08-26T14:00:00.000Z*
> Bronstein, Gewirtz & Grossman, LLC is investigating possible claims against Syros Pharmaceuticals, Inc. (SYRS) after the

### [Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | SYRS Stock News](https://longbridge.com/zh-CN/news/212419617.md)
*2024-08-23T23:15:00.000Z*
> Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for shareholders of Syros Pharmaceuticals, Inc. (SY